### **ILLUMINA INC.**

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock



## **Company Profile**

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

#### Financial figures, Fiscal year: from 01.01. to 31.12. 2023 2022 2021 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 2,609,000,000 3,561,000,000 2,713,000,000 Common stock capital 2,000,000 2,000,000 2,000,000 **Fixed assets** 7,502,000,000 8,691,000,000 12,504,000,000 Equity capital of a company 5.745.000.000 6.599.000.000 10.740.000.000 1.048.000.000 2.011.000.000 1.232.000.000 Cash and cash equivalents Accrued liabilities 0 0 Other assets **Current liabilities** 1,570,000,000 2,773,000,000 1,093,000,000 Prepayments and accrued income

	2,796,000,000		2,880,000,000		3,384,000,000
	-		-		-
	620,000,000		649,000,000		915,000,000
10,111,000,000	10,111,000,000	12,252,000,000	12,252,000,000	15,217,000,000	15,217,000,000
			2023	2022	2021
			US-GAAP	US-GAAP	US-GAAP
			12,010	11,500	9,800
			56.82%	53.86%	70.58%
			76.00%	85.66%	41.69%
			2023	2022	2021
					13.80%
	10,111,000,000	620,000,000	620,000,000 10,111,000,000 10,111,000,000 12,252,000,000	2023 US-GAAP 12,010 56.82% 76.00%	Color

# **ILLUMINA INC.**

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	4,504,000,000	4,584,000,000	4,526,000,000
Net income	-1,161,000,000	-4,404,000,000	762,000,000
EBIT	-1,023,665,400	-4,028,468,300	881,023,500
Operating income before taxes	-1,117,000,000	-4,336,000,000	884,000,000
Cash Flow	477,000,000	392,000,000	545,000,000
Net interest income	-19,000,000	-15,000,000	-61,000,000
Research and development expenses	1,330,000,000	1,321,000,000	1,185,000,000
Income taxes	44,000,000	68,000,000	122,000,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	349,632	371,623	430,570

## **Board of Directors**

Members of Management Board				
Stephen MacMillan	Chairman of Board of Directors			
Frances Arnold	Member of Board of Directors			
Gary Guthart	Member of Board of Directors			
Robert Epstein	Member of Board of Directors			
Scott Gottlieb	Member of Board of Directors			
Andrew Teno	Member of Board of Directors			
Caroline Dorsa	Member of Board of Directors			
Philip Schiller	Member of Board of Directors			
Scott Ullem	Member of Board of Directors			
Susan Siegel	Member of Board of Directors			
Francis deSouza	Chairman of Managing Board			
Alex Aravanis	Member of Executive Committee			
Joydeep Goswami	Member of Executive Committee			
Phil Febbo	Member of Executive Committee			
Aimee Hoyt	Member of Executive Committee			
Charles Dadswell	Member of Executive Committee			
Gretchen Weightman	Member of Executive Committee			
Kathryne Reeves	Member of Executive Committee			
Kevin Pegels	Member of Executive Committee			
Li Qing	Member of Executive Committee			
Nicole Berry	Member of Executive Committee			
Paula Dowdy	Member of Executive Committee			
Salli Schwartz	Member of Executive Committee			
Susan Tousi	Member of Executive Committee			